Pharmacogenomics of multiple sclerosis

Association of immune response gene polymorphisms with copaxone treatment efficacy

E. Yu Tsareva, O. G. Kulakova, O. Yu Makarycheva, A. N. Boyko, S. G. Shchur, N. Yu Lashch, N. F. Popova, E. I. Gusev, V. V. Bashinskaya, D. V. Lvov, Alexander Favorov, M. F. Ochs, O. O. Favorova

Research output: Contribution to journalArticle

Abstract

A complex association analysis of copaxone (glatiramer acetate) immunotherapy efficacy with allelic polymorphism of the number of immune response genes, including the genes for interferon β (IFNB1), transforming growth factor β1 (TGFB1), interferon γ (IFNG), tumor necrosis factor (TNF), interferon α/β receptor 1 (IFNAR1), CC chemokine receptor 5 (CCR5), interleukin 7 receptor subunit α (IL7RA), cytotoxic T-lymphocyte antigen 4 (CTLA4), and HLA class II histocompatibility antigen β chain (DRB1), was performed using the APSampler algorithm for 285 multiple sclerosis patients of Russian ethnicity. The results demonstrate that the polymorphic variants of CCR5, DRB1, IFNG, TGFB1, IFNAR1, IL7RA, and, possibly, TNF and CTLA4 contribute to the copaxone treatment response. Single alleles of CCR5 and DRB1 genes were reliably associated with treatment efficacy. Allelic variants of the other genes exerted a weaker, though still reliable, effect on the copaxone treatment response, but as part of bi- and triallelic combinations only. The study may provide a basis for a prognostic test allowing an individual choice of immune-modulating treatment for a patient with multiple sclerosis.

Original languageEnglish (US)
Pages (from-to)886-893
Number of pages8
JournalMolecular Biology
Volume45
Issue number6
DOIs
StatePublished - Dec 2011

Fingerprint

Pharmacogenetics
CCR5 Receptors
Multiple Sclerosis
CTLA-4 Antigen
Interferons
Genes
Interleukin-7 Receptors
Interferon Receptors
Histocompatibility
Tumor Necrosis Factor Receptors
Transforming Growth Factors
HLA Antigens
Immunotherapy
Therapeutics
Tumor Necrosis Factor-alpha
Alleles
Glatiramer Acetate

Keywords

  • APSampler
  • autoimmune inflammation
  • copaxone
  • cytokines
  • DNA
  • genes
  • glatiramer acetate
  • human
  • multiple sclerosis
  • PCR
  • pharmacogenomics
  • Russians
  • SNP

ASJC Scopus subject areas

  • Biophysics
  • Structural Biology

Cite this

Tsareva, E. Y., Kulakova, O. G., Makarycheva, O. Y., Boyko, A. N., Shchur, S. G., Lashch, N. Y., ... Favorova, O. O. (2011). Pharmacogenomics of multiple sclerosis: Association of immune response gene polymorphisms with copaxone treatment efficacy. Molecular Biology, 45(6), 886-893. https://doi.org/10.1134/S0026893311060185

Pharmacogenomics of multiple sclerosis : Association of immune response gene polymorphisms with copaxone treatment efficacy. / Tsareva, E. Yu; Kulakova, O. G.; Makarycheva, O. Yu; Boyko, A. N.; Shchur, S. G.; Lashch, N. Yu; Popova, N. F.; Gusev, E. I.; Bashinskaya, V. V.; Lvov, D. V.; Favorov, Alexander; Ochs, M. F.; Favorova, O. O.

In: Molecular Biology, Vol. 45, No. 6, 12.2011, p. 886-893.

Research output: Contribution to journalArticle

Tsareva, EY, Kulakova, OG, Makarycheva, OY, Boyko, AN, Shchur, SG, Lashch, NY, Popova, NF, Gusev, EI, Bashinskaya, VV, Lvov, DV, Favorov, A, Ochs, MF & Favorova, OO 2011, 'Pharmacogenomics of multiple sclerosis: Association of immune response gene polymorphisms with copaxone treatment efficacy', Molecular Biology, vol. 45, no. 6, pp. 886-893. https://doi.org/10.1134/S0026893311060185
Tsareva, E. Yu ; Kulakova, O. G. ; Makarycheva, O. Yu ; Boyko, A. N. ; Shchur, S. G. ; Lashch, N. Yu ; Popova, N. F. ; Gusev, E. I. ; Bashinskaya, V. V. ; Lvov, D. V. ; Favorov, Alexander ; Ochs, M. F. ; Favorova, O. O. / Pharmacogenomics of multiple sclerosis : Association of immune response gene polymorphisms with copaxone treatment efficacy. In: Molecular Biology. 2011 ; Vol. 45, No. 6. pp. 886-893.
@article{de184769ae90410f83fb4dd1d905d6e0,
title = "Pharmacogenomics of multiple sclerosis: Association of immune response gene polymorphisms with copaxone treatment efficacy",
abstract = "A complex association analysis of copaxone (glatiramer acetate) immunotherapy efficacy with allelic polymorphism of the number of immune response genes, including the genes for interferon β (IFNB1), transforming growth factor β1 (TGFB1), interferon γ (IFNG), tumor necrosis factor (TNF), interferon α/β receptor 1 (IFNAR1), CC chemokine receptor 5 (CCR5), interleukin 7 receptor subunit α (IL7RA), cytotoxic T-lymphocyte antigen 4 (CTLA4), and HLA class II histocompatibility antigen β chain (DRB1), was performed using the APSampler algorithm for 285 multiple sclerosis patients of Russian ethnicity. The results demonstrate that the polymorphic variants of CCR5, DRB1, IFNG, TGFB1, IFNAR1, IL7RA, and, possibly, TNF and CTLA4 contribute to the copaxone treatment response. Single alleles of CCR5 and DRB1 genes were reliably associated with treatment efficacy. Allelic variants of the other genes exerted a weaker, though still reliable, effect on the copaxone treatment response, but as part of bi- and triallelic combinations only. The study may provide a basis for a prognostic test allowing an individual choice of immune-modulating treatment for a patient with multiple sclerosis.",
keywords = "APSampler, autoimmune inflammation, copaxone, cytokines, DNA, genes, glatiramer acetate, human, multiple sclerosis, PCR, pharmacogenomics, Russians, SNP",
author = "Tsareva, {E. Yu} and Kulakova, {O. G.} and Makarycheva, {O. Yu} and Boyko, {A. N.} and Shchur, {S. G.} and Lashch, {N. Yu} and Popova, {N. F.} and Gusev, {E. I.} and Bashinskaya, {V. V.} and Lvov, {D. V.} and Alexander Favorov and Ochs, {M. F.} and Favorova, {O. O.}",
year = "2011",
month = "12",
doi = "10.1134/S0026893311060185",
language = "English (US)",
volume = "45",
pages = "886--893",
journal = "Molecular Biology",
issn = "0026-8933",
publisher = "Maik Nauka-Interperiodica Publishing",
number = "6",

}

TY - JOUR

T1 - Pharmacogenomics of multiple sclerosis

T2 - Association of immune response gene polymorphisms with copaxone treatment efficacy

AU - Tsareva, E. Yu

AU - Kulakova, O. G.

AU - Makarycheva, O. Yu

AU - Boyko, A. N.

AU - Shchur, S. G.

AU - Lashch, N. Yu

AU - Popova, N. F.

AU - Gusev, E. I.

AU - Bashinskaya, V. V.

AU - Lvov, D. V.

AU - Favorov, Alexander

AU - Ochs, M. F.

AU - Favorova, O. O.

PY - 2011/12

Y1 - 2011/12

N2 - A complex association analysis of copaxone (glatiramer acetate) immunotherapy efficacy with allelic polymorphism of the number of immune response genes, including the genes for interferon β (IFNB1), transforming growth factor β1 (TGFB1), interferon γ (IFNG), tumor necrosis factor (TNF), interferon α/β receptor 1 (IFNAR1), CC chemokine receptor 5 (CCR5), interleukin 7 receptor subunit α (IL7RA), cytotoxic T-lymphocyte antigen 4 (CTLA4), and HLA class II histocompatibility antigen β chain (DRB1), was performed using the APSampler algorithm for 285 multiple sclerosis patients of Russian ethnicity. The results demonstrate that the polymorphic variants of CCR5, DRB1, IFNG, TGFB1, IFNAR1, IL7RA, and, possibly, TNF and CTLA4 contribute to the copaxone treatment response. Single alleles of CCR5 and DRB1 genes were reliably associated with treatment efficacy. Allelic variants of the other genes exerted a weaker, though still reliable, effect on the copaxone treatment response, but as part of bi- and triallelic combinations only. The study may provide a basis for a prognostic test allowing an individual choice of immune-modulating treatment for a patient with multiple sclerosis.

AB - A complex association analysis of copaxone (glatiramer acetate) immunotherapy efficacy with allelic polymorphism of the number of immune response genes, including the genes for interferon β (IFNB1), transforming growth factor β1 (TGFB1), interferon γ (IFNG), tumor necrosis factor (TNF), interferon α/β receptor 1 (IFNAR1), CC chemokine receptor 5 (CCR5), interleukin 7 receptor subunit α (IL7RA), cytotoxic T-lymphocyte antigen 4 (CTLA4), and HLA class II histocompatibility antigen β chain (DRB1), was performed using the APSampler algorithm for 285 multiple sclerosis patients of Russian ethnicity. The results demonstrate that the polymorphic variants of CCR5, DRB1, IFNG, TGFB1, IFNAR1, IL7RA, and, possibly, TNF and CTLA4 contribute to the copaxone treatment response. Single alleles of CCR5 and DRB1 genes were reliably associated with treatment efficacy. Allelic variants of the other genes exerted a weaker, though still reliable, effect on the copaxone treatment response, but as part of bi- and triallelic combinations only. The study may provide a basis for a prognostic test allowing an individual choice of immune-modulating treatment for a patient with multiple sclerosis.

KW - APSampler

KW - autoimmune inflammation

KW - copaxone

KW - cytokines

KW - DNA

KW - genes

KW - glatiramer acetate

KW - human

KW - multiple sclerosis

KW - PCR

KW - pharmacogenomics

KW - Russians

KW - SNP

UR - http://www.scopus.com/inward/record.url?scp=82655189351&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=82655189351&partnerID=8YFLogxK

U2 - 10.1134/S0026893311060185

DO - 10.1134/S0026893311060185

M3 - Article

VL - 45

SP - 886

EP - 893

JO - Molecular Biology

JF - Molecular Biology

SN - 0026-8933

IS - 6

ER -